$SCNI News

Scinai Immunotherapeutics Ltd. (SCNI) Q2 2026 Earnings Call Transcript

Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum

Scinai Immunotherapeutics H1 Net Income $1.6M Vs Loss $4.1M Prior Year; Revenues $949K Up From $773K YoY; Continues To Pursue ~$5M In CDMO Revenues For 2026

Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives

Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility

Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

Scinai Immunotherapeutics shares are trading higher after the company announced a $2.61 million private placement financing.

Scinai Immunotherapeutics shares are trading higher after the company announced a $2.61 million private placement financing.

Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today

Scinai Immunotherapeutics Enters Securities Purchase Agreement For Up To 5.21M ADS And Warrants Priced At $0.48 Per Unit

Scinai Immunotherapeutics Completes Strategic Corporate Reorganization Establishing CDMO Platform Alongside Streamlined R&D Organization

Scinai Immunotherapeutics shares are trading higher after the company reported a year-over-year increase in FY sales results.

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

Scinai Immunotherapeutics FY EPS $(3.56), Sales $1.311M Up From $658.000K YoY

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

Scinai Immunotherapeutics To Present Its Growing Pipeline Of Antibody-Based Therapeutics Targeting Autoimmune And Inflammatory Diseases At BIO-Europe Spring 2026

Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

Scinai Immunotherapeutics Receives Non-Compliance Notification From Nasdaq

Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept